JERSEY, Channel Islands, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Quotient Limited ("Quotient") (Nasdaq:QTNT), a commercial-stage diagnostics company, today announced the appointment of Sarah O'Connor to the Company's Board of Directors. Ms. O'Connor will also serve on the Board's Nominating and Corporate Governance Committee. Most recently, Ms. O'Connor served as Senior Vice President, Strategic Development and Chief Legal Officer of Arch Chemicals, Inc., a publicly traded biocides company with sales of over $1.0 billion acquired by Lonza Group Ltd in October of 2011. "Sarah brings over twenty-five years experience as a senior executive within a number of major US corporations, where she held key positions spanning legal affairs and corporate governance, strategic planning and development and risk management," commented Paul Cowan, Quotient's Chairman and Chief Executive Officer. "We are delighted to have Sarah join our Board and we look forward to working with her as we transform the global transfusion diagnostic marketplace."
About Quotient Limited
Quotient is an established, commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the development and commercialization of innovative tests, currently focused on blood grouping and serological disease screening. Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by any commercially available transfusion diagnostic instrument platform. The company's operations are based in Edinburgh, Scotland; Newtown, Pennsylvania; and Eysins, Switzerland.
CONTACT: Stephen Unger, Chief Financial Officer firstname.lastname@example.org (212) 228-7572Source:Quotient Biodiagnostics, Inc.